Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417673 · ClinicalTrials.gov registry record
Living With Sickle Cell Disease in the COVID-19 Pandemic
A clinical trial of Pain and Anxiety, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 186
- Enrollment target
- 1
- Study location
NCT04417673: Completed study of Pain and Anxiety, sponsored by National Human Genome Research Institute (NHGRI).
NCT04417673 is a study of Pain and Anxiety that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 186 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04417673, a study of Pain and Anxiety, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD also are at greater risk for respiratory infections and lung problems. Researchers want to study how this population s stress, anxiety, fear, pain, sleep, and health care use are being affected by the COVID-19 pandemic. Objective: To study the extent and impact of life changes induced by the COVID-19 pandemic on people living with SCD in the U.S. Eligibility: People age 18 and older with SCD who live in the U.S. Design: Participants will complete a survey online. The questions will focus on the following: Medical history Mental and physical health Demographics Stress Resilience Health care use COVID-19 Beliefs about medical mistrust and participation in research. At the end of the survey, participants will be asked if they would like to take the survey again in the future. If they reply "yes," then they will be contacted by the study team in 6-9 months to take the survey again. They may complete the survey again in 6-8 months, 12-15 months, and 18-21 months. The survey should take less than 40 minutes to complete. Participants' data will be coded to protect their privacy. The coded data may be shared with other researchers.
Primary Outcome
We will examine how the COVID-19 pandemic impacts stress levels among individuals with sickle cell disease (SCD).
Conditions Studied
Study Locations (1)
Maryland
- National Human Genome Research Institute (NHGRI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2022-05-18 |
What the finished NCT04417673 record still lists
NCT04417673 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (39% lower).
The record links to 5 conditions, with Pain appearing as the primary indexed condition, and to 0 interventions.
NCT04417673 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04417673 about?
NCT04417673 is a clinical study titled "Living With Sickle Cell Disease in the COVID-19 Pandemic". Background: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD a...
What is the current status of trial NCT04417673?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2020-06-15. Estimated completion is 2022-05-18.
What conditions does trial NCT04417673 study?
This clinical trial studies the following conditions: Pain, Anxiety, Sickle Cell Disease, Health Care Utilization, Isolation.
Who is sponsoring clinical trial NCT04417673?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04417673 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04417673's enrollment target sits among peer trials
186 96th of 374 higher than 279 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Reliability of Pupil Response to Acute Pain
RECRUITING
-
Pain With Dementia
RECRUITING · NA
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Defense and Veterans Center for Integrative Pain Management (DVCIPM) Pain Registry Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI